

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

RENEWAL OF CAUTIONARY ANNOUNCEMENT – API BUSINESS

Shareholders are referred to the cautionary announcement released by Aspen on 9 September 2021, and its subsequent renewal of 21 October 2021, in which shareholders were advised that Aspen had received two unsolicited offers for its active pharmaceutical ingredient business (“API Business”)¹. This announcement also confirmed that Aspen had decided to embark on a structured process to facilitate offers for all or parts of its API Business from those parties that submitted the unsolicited offers and other selected interested parties.

Shareholders are advised that this structured process remains ongoing and may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen’s securities.

Durban
03 December 2021

Sponsor
Investec Bank Limited

¹ Comprising the Chemicals and Biochem segments of Aspen’s Manufacturing operations, situated in the Netherlands, South Africa and the United States.